$1.80
2.27% today
Nasdaq, Aug 26, 07:15 pm CET
ISIN
US45719W1062
Symbol
IKT

Inhibikase Therapeutics Inc Stock price

$1.76
-0.01 0.57% 1M
-0.48 21.43% 6M
-1.49 45.85% YTD
+0.31 21.38% 1Y
-3.52 66.67% 3Y
-57.64 97.04% 5Y
-57.64 97.04% 10Y
-57.64 97.04% 20Y
Nasdaq, Closing price Mon, Aug 25 2025
-0.13 6.88%
ISIN
US45719W1062
Symbol
IKT
Industry

Key metrics

Basic
Market capitalization
$131.2m
Enterprise Value
$43.5m
Net debt
positive
Cash
$87.7m
Shares outstanding
74.5m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
negative
P/B
1.6
Financial Health
Equity Ratio
96.2%
Return on Equity
-29.0%
ROCE
-55.2%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-44.1m | -
EBIT
$-44.2m | $-38.9m
Net Income
$-41.5m | $-32.1m
Free Cash Flow
$-20.4m
Growth (TTM | estimate)
Revenue
-100.0% | -
EBITDA
-132.6% | -
EBIT
-132.5% | -36.1%
Net Income
-125.7% | -16.7%
Free Cash Flow
-23.6%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-0.5
FCF per Share
$-0.3
Short interest
10.1%
Employees
16
Rev per Employee
$0.0
Show more

Is Inhibikase Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,019 stocks worldwide.

Inhibikase Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Inhibikase Therapeutics Inc forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Inhibikase Therapeutics Inc forecast:

Buy
71%
Hold
29%

Financial data from Inhibikase Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 19 19
164% 164%
-
- Research and Development Expense 27 27
125% 125%
-
-44 -44
133% 133%
-
- Depreciation and Amortization 0.05 0.05
67% 67%
-
EBIT (Operating Income) EBIT -44 -44
132% 132%
-
Net Profit -42 -42
126% 126%
-

In millions USD.

Don't miss a Thing! We will send you all news about Inhibikase Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Inhibikase Therapeutics Inc Stock News

Neutral
GlobeNewsWire
7 days ago
BOSTON and ATLANTA, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of pulmonary arterial hypertension (“PAH”), today announced the appointment of veteran biopharma executive Timothy Pigot as the Company's Chief Commercial and Strategy Officer. “Tim Pig...
Neutral
GlobeNewsWire
12 days ago
BOSTON and ATLANTA, Aug. 14, 2025 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing therapeutics to modify the course of cardiopulmonary diseases namely, Pulmonary Arterial Hypertension (“PAH”), today reported financial results for the quarter ended June 30, 2025 and highlighted recent developments.
Neutral
GlobeNewsWire
3 months ago
Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension Advancing IKT-001 into a Late-Stage Clinical Trial Program in Pulmonary Arterial Hypertension
More Inhibikase Therapeutics Inc News

Company Profile

Inhibikase Therapeutics, Inc. provides infectious disease treatments. It develops small molecule platform for treating both bacterial and viral infectious diseases. It operates through RAMP™ Drug Innovation Engine technology. The company was founded by Milton H. Werner in September 2008 and is headquartered in Atlanta, GA.

Head office United States
CEO Mark Iwicki
Employees 16
Founded 2008
Website www.inhibikase.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today